Thomas R. Meinel, MD; Duncan Wilson, PhD; Henrik Gensicke, MD; et al.
open access
JAMA Neurol. 2023;80(3):233-243. doi:10.1001/jamaneurol.2022.4782
This cohort study evaluates the risk of symptomatic intracranial hemorrhage associated with use of intravenous thrombolysis in patients with recent direct oral anticoagulant ingestion.
Hyo-Jung Kim, PhD; Ji-Soo Kim, MD, PhD; Kwang-Dong Choi, MD, PhD; et al.
free access
has multimedia
JAMA Neurol. 2023;80(3):244-250. doi:10.1001/jamaneurol.2022.4944
This randomized clinical trial assesses the efficacy of a web-based diagnosis and treatment of benign paroxysmal positional vertigo when it recurs in patients with confirmed and treated benign paroxysmal positional vertigo.
Jacqueline J. Bosch, PhD; Martin J. O鈥橠onnell, MD; Peggy Gao, MSc; et al.
free access
JAMA Neurol. 2023;80(3):251-259. doi:10.1001/jamaneurol.2022.5088
This randomized clinical trial investigates the effectiveness of a polypill in the reduction of cognitive and functional decline in individuals at intermediate risk of cardiovascular disease.
Holly Elser, MD, PhD; Rebecca F. Gottesman, MD, PhD; Alexa E. Walter, PhD; et al.
free access
JAMA Neurol. 2023;80(3):260-269. doi:10.1001/jamaneurol.2022.5024
This cohort study uses Atherosclerosis Risk in Communities study data to evaluate the association of head injury with long-term all-cause mortality risk in adults.
Peter Mitchell, MMed; Sarah C. M. Lee, MBBS; Peter E. Yoo, PhD; et al.
free access
JAMA Neurol. 2023;80(3):270-278. doi:10.1001/jamaneurol.2022.4847
This case series assesses the safety of an endovascular brain-computer interface and feasibility of using the system to control a computer by thought.
Giancarlo Logroscino, MD; Marco Piccininni, PhD; Caroline Graff, MD; et al.
open access
JAMA Neurol. 2023;80(3):279-286. doi:10.1001/jamaneurol.2022.5128
This cohort study analyzes age- and sex-specific incidence rates of frontotemporal lobar degeneration鈥搑elated disorders by phenotype across 9 European countries.
Stephanie Meier, MSc; Eline A.J. Willemse, PhD; Sabine Schaedelin, MSc; et al.
free access
JAMA Neurol. 2023;80(3):287-297. doi:10.1001/jamaneurol.2022.5250
This cohort study investigates if concentrations of serum glial fibrillary acidic protein and neurofilament light chain are associated with and prognostic for disease progression in patients with multiple sclerosis.
Bernhard Hemmer, MD; Heinz Wiendl, MD; Karsten Roth, PhD; et al.
open access
JAMA Neurol. 2023;80(3):298-307. doi:10.1001/jamaneurol.2022.5007
This randomized clinical trial evaluates matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizumab in patients with relapsing-remitting multiple sclerosis.